ACUTE MYELOGENOUS LEUKEMIA (AML)
Clinical trials for ACUTE MYELOGENOUS LEUKEMIA (AML) explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOGENOUS LEUKEMIA (AML) trials appear
Sign up with your email to follow new studies for ACUTE MYELOGENOUS LEUKEMIA (AML), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for fanconi anemia: gentler transplant may reduce side effects
Disease control Recruiting nowThis study tests a stem cell transplant using lower doses of chemotherapy for people with Fanconi anemia who don't have a perfectly matched donor. The goal is to reduce serious side effects while still helping the body accept new blood-forming cells. About 70 participants will re…
Matched conditions: ACUTE MYELOGENOUS LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated May 26, 2026 02:33 UTC
-
New combo therapy aims to fight advanced breast cancer and melanoma
Disease control Recruiting nowThis early-phase study is testing a combination of two drugs, alpelisib and pembrolizumab, in people with metastatic breast cancer or melanoma that has spread to the brain. The main goal is to find a safe dose and check for side effects. About 50 adults whose cancer has not respo…
Matched conditions: ACUTE MYELOGENOUS LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 02:31 UTC
-
New cord blood transplant method aims to beat High-Risk blood cancers
Disease control Recruiting nowThis study tests an improved method for cord blood transplants in adults with hard-to-treat blood cancers like leukemia and lymphoma. The approach uses a standard set of steps—including chemotherapy, radiation, and careful follow-up—to help the body accept the new stem cells. Res…
Matched conditions: ACUTE MYELOGENOUS LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 02:30 UTC
-
New antibody combo aims to target leukemia stem cells
Disease control Recruiting nowThis study tests a new drug called nadunolimab combined with standard treatments (azacitidine, with or without venetoclax) in 40 adults with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal is to see if the combination is safe and can target leuk…
Matched conditions: ACUTE MYELOGENOUS LEUKEMIA (AML)
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:54 UTC